Generation of B-cell-based cellular vaccine for cancer in murine models

David Hou; Joshua L. Katz; Catalina Lee-Chang

doi:10.1016/j.xpro.2023.102219

Generation of B-cell-based cellular vaccine for cancer in murine models

David Hou, Joshua L. Katz, Catalina Lee-Chang^*

^*Corresponding author for this work

Neurological Surgery

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

A B-cell-based cellular vaccine (B_Vax), produced from 4-1BBL⁺ B cells, can select tumor-specific B cells that, upon ex vivo culture, can generate tumor-specific antibodies and activate T cells. Here, we present a protocol to generate a B-cell-based vaccine in a CT2A orthotopic glioma murine model. We describe steps for B_Vax production involving glioma cell implantation, tissue harvesting, 4-1BBL⁺ B cell isolation, and activation. We also describe assessing B_Vax phenotype in vitro and in vivo functional status. For complete details on the use and execution of this protocol, please refer to Lee-Chang et al. (2021).¹

Original language	English (US)
Article number	102219
Journal	STAR Protocols
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/j.xpro.2023.102219
State	Published - Jun 16 2023

Funding

This study was supported by the National Institutes of Health (R37CA258426, P50CA221747) and the American Brain Tumor Association. The National Cancer Institute Cancer Center Support Grant CA060553 supports the Northwestern Flow Cytometry Core Facility. D.H. J.L.K. and C.L-.C. conceived the study, designed experiments, interpreted results, and wrote the manuscript. C.L-.C. is an inventor of “B-cell based immunotherapy for the treatment of glioblastoma and other cancers” (WO2022040202A1). This study was supported by the National Institutes of Health ( R37CA258426 , P50CA221747 ) and the American Brain Tumor Association . The National Cancer Institute Cancer Center Support Grant CA060553 supports the Northwestern Flow Cytometry Core Facility.

Keywords

Cancer
Immunology

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
General Immunology and Microbiology
General Neuroscience

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.xpro.2023.102219

Cite this

@article{7bf3ee9ecbb145dea2c12b2c343ed459,

title = "Generation of B-cell-based cellular vaccine for cancer in murine models",

abstract = "A B-cell-based cellular vaccine (BVax), produced from 4-1BBL+ B cells, can select tumor-specific B cells that, upon ex vivo culture, can generate tumor-specific antibodies and activate T cells. Here, we present a protocol to generate a B-cell-based vaccine in a CT2A orthotopic glioma murine model. We describe steps for BVax production involving glioma cell implantation, tissue harvesting, 4-1BBL+ B cell isolation, and activation. We also describe assessing BVax phenotype in vitro and in vivo functional status. For complete details on the use and execution of this protocol, please refer to Lee-Chang et al. (2021).1",

keywords = "Cancer, Immunology",

author = "David Hou and Katz, {Joshua L.} and Catalina Lee-Chang",

note = "Funding Information: This study was supported by the National Institutes of Health (R37CA258426, P50CA221747) and the American Brain Tumor Association. The National Cancer Institute Cancer Center Support Grant CA060553 supports the Northwestern Flow Cytometry Core Facility. D.H. J.L.K. and C.L-.C. conceived the study, designed experiments, interpreted results, and wrote the manuscript. C.L-.C. is an inventor of “B-cell based immunotherapy for the treatment of glioblastoma and other cancers” (WO2022040202A1). Funding Information: This study was supported by the National Institutes of Health ( R37CA258426 , P50CA221747 ) and the American Brain Tumor Association . The National Cancer Institute Cancer Center Support Grant CA060553 supports the Northwestern Flow Cytometry Core Facility. Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = jun,

day = "16",

doi = "10.1016/j.xpro.2023.102219",

language = "English (US)",

volume = "4",

journal = "STAR Protocols",

issn = "2666-1667",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Generation of B-cell-based cellular vaccine for cancer in murine models

AU - Hou, David

AU - Katz, Joshua L.

AU - Lee-Chang, Catalina

N1 - Funding Information: This study was supported by the National Institutes of Health (R37CA258426, P50CA221747) and the American Brain Tumor Association. The National Cancer Institute Cancer Center Support Grant CA060553 supports the Northwestern Flow Cytometry Core Facility. D.H. J.L.K. and C.L-.C. conceived the study, designed experiments, interpreted results, and wrote the manuscript. C.L-.C. is an inventor of “B-cell based immunotherapy for the treatment of glioblastoma and other cancers” (WO2022040202A1). Funding Information: This study was supported by the National Institutes of Health ( R37CA258426 , P50CA221747 ) and the American Brain Tumor Association . The National Cancer Institute Cancer Center Support Grant CA060553 supports the Northwestern Flow Cytometry Core Facility. Publisher Copyright: © 2023 The Author(s)

PY - 2023/6/16

Y1 - 2023/6/16

N2 - A B-cell-based cellular vaccine (BVax), produced from 4-1BBL+ B cells, can select tumor-specific B cells that, upon ex vivo culture, can generate tumor-specific antibodies and activate T cells. Here, we present a protocol to generate a B-cell-based vaccine in a CT2A orthotopic glioma murine model. We describe steps for BVax production involving glioma cell implantation, tissue harvesting, 4-1BBL+ B cell isolation, and activation. We also describe assessing BVax phenotype in vitro and in vivo functional status. For complete details on the use and execution of this protocol, please refer to Lee-Chang et al. (2021).1

AB - A B-cell-based cellular vaccine (BVax), produced from 4-1BBL+ B cells, can select tumor-specific B cells that, upon ex vivo culture, can generate tumor-specific antibodies and activate T cells. Here, we present a protocol to generate a B-cell-based vaccine in a CT2A orthotopic glioma murine model. We describe steps for BVax production involving glioma cell implantation, tissue harvesting, 4-1BBL+ B cell isolation, and activation. We also describe assessing BVax phenotype in vitro and in vivo functional status. For complete details on the use and execution of this protocol, please refer to Lee-Chang et al. (2021).1

KW - Cancer

KW - Immunology

UR - http://www.scopus.com/inward/record.url?scp=85152727490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152727490&partnerID=8YFLogxK

U2 - 10.1016/j.xpro.2023.102219

DO - 10.1016/j.xpro.2023.102219

M3 - Article

C2 - 37083319

AN - SCOPUS:85152727490

SN - 2666-1667

VL - 4

JO - STAR Protocols

JF - STAR Protocols

IS - 2

M1 - 102219

ER -

Generation of B-cell-based cellular vaccine for cancer in murine models

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this